Tina Varughese
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations.
Across 139 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$784
- GSK$398
- Regeneron Healthcare Solutions, Inc.$390
- Takeda Pharmaceuticals U.S.A., Inc.$313
- Sanofi$184
- Mylan Specialty L.p.$149
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,465100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $784 |
| GSK | 20 | $398 |
| Regeneron Healthcare Solutions, Inc. | 10 | $390 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $313 |
| Sanofi | 8 | $184 |
| Mylan Specialty L.p. | 5 | $149 |
| Mallinckrodt Hospital Products Inc. | 4 | $135 |
| Boehringer Ingelheim | 4 | $126 |
| Philips North America LLC | 5 | $95 |
| Pulmonx Corporation | 4 | $95 |
| AbbVie | 5 | $88 |
| Novartis | 4 | $83 |
| Viatris Specialty LLC | 3 | $75 |
| Bayer | 3 | $60 |
| Novo Nordisk | 3 | $55 |
| Merck | 3 | $54 |
| Greer Laboratories, Inc. | 2 | $47 |
| Amgen | 3 | $44 |
| Electromed, Inc. | 2 | $36 |
| Harmony Biosciences LLC | 1 | $31 |
| Insmed, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $22 |
| Resmed Corp | 1 | $22 |
| Covis Pharma GmbH | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,465 in reported general payments places this provider in the 85th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 578 | $774,103 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 154 | $193,334 |
| Fasenra PenBenralizumab | 21 | $119,997 |
| Breo ElliptaFluticasone/Vilanterol | 93 | $80,915 |
| Dupixent PenDupilumab | 12 | $70,095 |
| Dupixent SyringeDupilumab | 16 | $60,385 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $56,032 |
| Spiriva RespimatTiotropium Bromide | 55 | $55,939 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $37,720 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 920 | $34,452 |
| Incruse ElliptaUmeclidinium Bromide | 55 | $34,244 |
| Advair HfaFluticasone Propion/Salmeterol | 40 | $28,956 |
| Spiriva HandihalerTiotropium Bromide | 27 | $27,749 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $20,617 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $14,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $398 | $950,715792 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $784 | $239,709243 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $126 | $70,04868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 523 family providers in Delaware.
Other family in Dover
- Heather GrahamDover$6K
- Shannon CullinDover$5K
- Amanda BooneDover$5K
- Patricia PowellDover$3K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.